Literature DB >> 15902560

Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease.

R J Kalliokoski1, K K Kalliokoski, J Sundell, E Engblom, M Penttinen, I Kantola, O T Raitakari, J Knuuti, P Nuutila.   

Abstract

Fabry disease (McKusick 301500) is an X-linked lysosomal storage disorder due to deficient alpha-galactosidase A activity, which leads to accumulation of glycosphingolipids, especially in vascular smooth-muscle and endothelial cells. The effect of this accumulation on peripheral and cardiac vascular function is poorly known. We studied 15 Fabry patients (mean age 35 years and mean BMI 24.8 kg/m2) and 30 age- and BMI-matched healthy controls to examine whether myocardial perfusion reserve and peripheral artery endothelial function are altered. Myocardial perfusion was measured at rest and during dipyridamole-induced hyperaemia by positron emission tomography and H2(15)O. Myocardial blood flow reserve was calculated as the ratio between the dipyridamole-induced maximal blood flow and resting blood flow. Peripheral artery endothelial function was assessed by measuring the brachial artery flow-mediated dilatation using ultrasound at rest and during reactive hyperaemia. The myocardial perfusion reserve was significantly lower in Fabry patients than in controls (3.3+/-1.2 vs 4.4+/-1.6, p=0.02), while the brachial artery flow-mediated dilatation was similar (5.9%+/-3.9% vs 4.5%+/-3.6%, p=0.27). Thus, inFabry disease, myocardial perfusion reserve is reduced while the peripheral artery endothelial function is preserved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15902560     DOI: 10.1007/s10545-005-0563-2

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  24 in total

Review 1.  Quantification of PET Myocardial Blood Flow.

Authors:  Matthieu Pelletier-Galarneau; Patrick Martineau; Georges El Fakhri
Journal:  Curr Cardiol Rep       Date:  2019-02-28       Impact factor: 2.931

2.  The potential for PET-guided revascularization of coronary artery disease.

Authors:  Matthieu Pelletier-Galarneau; Terrence D Ruddy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-02       Impact factor: 9.236

Review 3.  Microvascular dysfunction in infiltrative cardiomyopathies.

Authors:  Ornella Rimoldi; Francesco Maranta
Journal:  J Nucl Cardiol       Date:  2017-07-11       Impact factor: 5.952

4.  Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC.

Authors:  Venkatesh L Murthy; Timothy M Bateman; Rob S Beanlands; Daniel S Berman; Salvador Borges-Neto; Panithaya Chareonthaitawee; Manuel D Cerqueira; Robert A deKemp; E Gordon DePuey; Vasken Dilsizian; Sharmila Dorbala; Edward P Ficaro; Ernest V Garcia; Henry Gewirtz; Gary V Heller; Howard C Lewin; Saurabh Malhotra; April Mann; Terrence D Ruddy; Thomas H Schindler; Ronald G Schwartz; Piotr J Slomka; Prem Soman; Marcelo F Di Carli; Andrew Einstein; Raymond Russell; James R Corbett
Journal:  J Nucl Cardiol       Date:  2018-02       Impact factor: 5.952

5.  Structural and functional changes in peripheral vasculature of Fabry patients.

Authors:  Riikka J Kalliokoski; Kari K Kalliokoski; Maila Penttinen; Ilkka Kantola; Aila Leino; Jorma S Viikari; Olli Simell; Pirjo Nuutila; Olli T Raitakari
Journal:  J Inherit Metab Dis       Date:  2006-08-12       Impact factor: 4.982

6.  The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease.

Authors:  R J Kalliokoski; I Kantola; K K Kalliokoski; E Engblom; J Sundell; J C Hannukainen; T Janatuinen; O T Raitakari; J Knuuti; M Penttinen; J Viikari; P Nuutila
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

7.  Intravascular ultrasound assessment of coronary artery involvement in Fabry disease.

Authors:  T Kovarnik; G S Mintz; D Karetova; J Horak; J Bultas; R Skulec; H Skalicka; M Aschermann; M Elleder; A Linhart
Journal:  J Inherit Metab Dis       Date:  2008-11-08       Impact factor: 4.982

Review 8.  Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.

Authors:  Brendan N Putko; Kevin Wen; Richard B Thompson; John Mullen; Miriam Shanks; Haran Yogasundaram; Consolato Sergi; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

9.  Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse.

Authors:  James L Park; Liming Shu; James A Shayman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-06       Impact factor: 4.733

Review 10.  Fabry's disease: an example of cardiorenal syndrome type 5.

Authors:  Aashish Sharma; Marco Sartori; Jose J Zaragoza; Gianluca Villa; Renhua Lu; Elena Faggiana; Alessandra Brocca; Luca Di Lullo; Sandro Feriozzi; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2015-11       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.